AACR 2016: Five-year survival rates for nivolumab-treated metastatic melanoma patients much higher than historical rates
More than a third of metastatic melanoma patients (34 percent) who received the anti-PD-1 immunotherapeutic…
Browsing: anti-PD-1 immunotherapeutic nivolumab